Cargando…
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
BACKGROUND AND HYPOTHESIS: Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland. ST...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212108/ https://www.ncbi.nlm.nih.gov/pubmed/35524479 http://dx.doi.org/10.1093/schbul/sbac039 |
_version_ | 1784730505931915264 |
---|---|
author | Taipale, Heidi Tanskanen, Antti Luykx, Jurjen J Solmi, Marco Leucht, Stefan Correll, Christoph U Tiihonen, Jari |
author_facet | Taipale, Heidi Tanskanen, Antti Luykx, Jurjen J Solmi, Marco Leucht, Stefan Correll, Christoph U Tiihonen, Jari |
author_sort | Taipale, Heidi |
collection | PubMed |
description | BACKGROUND AND HYPOTHESIS: Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland. STUDY METHODS: We studied the risk of rehospitalization (Adjusted Hazard Ratio, aHR) associated with six antipsychotic monotherapy dose categories (as time-varying dose, measured in defined daily dose, DDDs/day) in a nationwide cohort of persons diagnosed with schizophrenia (n = 61 889), using within-individual analyses to eliminate selection bias. STUDY RESULTS: Among the 15 most widely used antipsychotics, 13 had a U- or J-shaped dose-response curve, showing the lowest risks of relapse for doses of 0.6–<1.1 DDDs/day vs nonuse of antipsychotics. The exceptions were oral perphenazine (aHR = 0.72, 95% CI = 0.68–0.76, <0.6 DDDs/day), and olanzapine-long-acting injectable (LAI), which had the lowest aHR of any antipsychotic (aHR = 0.17, 95% CI = 0.11–0.25, 1.4–<1.6 DDDs/day). Certain risperidone and perphenazine doses <0.9 DDD/day were associated with 21%–45% lower risk of rehospitalization (P < .001) than the standard dose of 0.9–1.1 DDD/day (ie, 5 mg for risperidone and 30 mg for perphenazine). CONCLUSIONS: For most antipsychotics, the risk of severe relapse was the lowest during use of standard dose. Our results suggest that olanzapine LAI is highly effective in dose ranges >0.9 DDD/day, and especially at 1.4–<1.6 DDDs/day (405 mg/4 weeks) associated with substantially lower risk of rehospitalization than any dose of any other antipsychotic. The current WHO standard dose definitions appear to be clearly too high for perphenazine and somewhat too high for risperidone. |
format | Online Article Text |
id | pubmed-9212108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92121082022-06-22 Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia Taipale, Heidi Tanskanen, Antti Luykx, Jurjen J Solmi, Marco Leucht, Stefan Correll, Christoph U Tiihonen, Jari Schizophr Bull Regular Articles BACKGROUND AND HYPOTHESIS: Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland. STUDY METHODS: We studied the risk of rehospitalization (Adjusted Hazard Ratio, aHR) associated with six antipsychotic monotherapy dose categories (as time-varying dose, measured in defined daily dose, DDDs/day) in a nationwide cohort of persons diagnosed with schizophrenia (n = 61 889), using within-individual analyses to eliminate selection bias. STUDY RESULTS: Among the 15 most widely used antipsychotics, 13 had a U- or J-shaped dose-response curve, showing the lowest risks of relapse for doses of 0.6–<1.1 DDDs/day vs nonuse of antipsychotics. The exceptions were oral perphenazine (aHR = 0.72, 95% CI = 0.68–0.76, <0.6 DDDs/day), and olanzapine-long-acting injectable (LAI), which had the lowest aHR of any antipsychotic (aHR = 0.17, 95% CI = 0.11–0.25, 1.4–<1.6 DDDs/day). Certain risperidone and perphenazine doses <0.9 DDD/day were associated with 21%–45% lower risk of rehospitalization (P < .001) than the standard dose of 0.9–1.1 DDD/day (ie, 5 mg for risperidone and 30 mg for perphenazine). CONCLUSIONS: For most antipsychotics, the risk of severe relapse was the lowest during use of standard dose. Our results suggest that olanzapine LAI is highly effective in dose ranges >0.9 DDD/day, and especially at 1.4–<1.6 DDDs/day (405 mg/4 weeks) associated with substantially lower risk of rehospitalization than any dose of any other antipsychotic. The current WHO standard dose definitions appear to be clearly too high for perphenazine and somewhat too high for risperidone. Oxford University Press 2022-05-07 /pmc/articles/PMC9212108/ /pubmed/35524479 http://dx.doi.org/10.1093/schbul/sbac039 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Articles Taipale, Heidi Tanskanen, Antti Luykx, Jurjen J Solmi, Marco Leucht, Stefan Correll, Christoph U Tiihonen, Jari Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title_full | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title_fullStr | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title_full_unstemmed | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title_short | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia |
title_sort | optimal doses of specific antipsychotics for relapse prevention in a nationwide cohort of patients with schizophrenia |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212108/ https://www.ncbi.nlm.nih.gov/pubmed/35524479 http://dx.doi.org/10.1093/schbul/sbac039 |
work_keys_str_mv | AT taipaleheidi optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT tanskanenantti optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT luykxjurjenj optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT solmimarco optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT leuchtstefan optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT correllchristophu optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia AT tiihonenjari optimaldosesofspecificantipsychoticsforrelapsepreventioninanationwidecohortofpatientswithschizophrenia |